{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:21:51Z","timestamp":1792812111702,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T00:00:00Z","timestamp":1234483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00277-009-0706-x","type":"journal-article","created":{"date-parts":[[2009,2,13]],"date-time":"2009-02-13T10:49:00Z","timestamp":1234522140000},"page":"967-971","source":"Crossref","is-referenced-by-count":31,"title":["Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms"],"prefix":"10.1007","volume":"88","author":[{"given":"Domenica","family":"Caramazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Caracciolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Malato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Saccullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Cigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Schinocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlando","family":"Quintini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,13]]},"reference":[{"key":"706_CR1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275\u201390","journal-title":"Br J Haematol"},{"key":"706_CR2","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u201332","journal-title":"J Clin Oncol"},{"key":"706_CR3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755\u201361","journal-title":"Am J Med"},{"key":"706_CR4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","volume":"81","author":"AP Wolanskyj","year":"2006","unstructured":"Wolanskyj AP, Schwager SM, McClure RF et al (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81:159\u201366","journal-title":"Mayo Clin Proc"},{"key":"706_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2005.05.023","volume":"42","author":"A Falanga","year":"2005","unstructured":"Falanga A, Marchetti M, Barbui T et al (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 42:239\u2013247","journal-title":"Semin Hematol"},{"key":"706_CR6","first-page":"169","volume":"91","author":"E Arellano-Rodrigo","year":"2006","unstructured":"Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC et al (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91:169\u2013175","journal-title":"Haematologica"},{"key":"706_CR7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","volume":"131","author":"AP Wolanskyj","year":"2005","unstructured":"Wolanskyj AP, Lasho TL, Schwager SM et al (2005) JAK2V617F mutation in essential thrombocythaemia: clinical implications and long-term prognostic relevance. Br J Haematol 131:208\u2013213","journal-title":"Br J Haematol"},{"key":"706_CR8","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","volume":"109","author":"A Carobbio","year":"2007","unstructured":"Carobbio A, Finazzi G, Guerini V et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 109:2310\u20133","journal-title":"Blood"},{"key":"706_CR9","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446\u201352","journal-title":"Blood"},{"key":"706_CR10","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood-2008-03-146001","volume":"112","author":"MN Kundranda","year":"2008","unstructured":"Kundranda MN, Maiti B, Iqbal N et al (2008) The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in myeloproliferative disorders (MPD\u2019s). Blood 112:2803 (Abs)","journal-title":"Blood"},{"key":"706_CR11","first-page":"29","volume":"34","author":"S Murphy","year":"1997","unstructured":"Murphy S, Peterson P, Iland H et al (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 34:29\u201339","journal-title":"Semin Hematol"},{"key":"706_CR12","doi-asserted-by":"crossref","unstructured":"Pearson TC, Messinezy M, Westwood N, et al. (2000). A polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematology Am Soc Hematol Educ Program 51-68","DOI":"10.1182\/asheducation-2000.1.51"},{"key":"706_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","volume":"353","author":"T Barbui","year":"2005","unstructured":"Barbui T, Finazzi G (2005) When and how to treat essential thrombocythemia. New Engl J Med 353:85\u201386","journal-title":"New Engl J Med"},{"key":"706_CR14","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"issue":"3","key":"706_CR15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, Strand J, Li CY et al (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138(3):354\u20138","journal-title":"Br J Haematol"},{"key":"706_CR16","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"706_CR17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","volume":"132","author":"B Cheung","year":"2005","unstructured":"Cheung B, Radia D, Pantelidis P et al (2005) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 132:244\u2013250","journal-title":"Br J Haematol"},{"key":"706_CR18","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","volume":"19","author":"E Antonioli","year":"2005","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847\u20131849","journal-title":"Leukemia"},{"issue":"1","key":"706_CR19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","volume":"33","author":"IJ Dahabreh","year":"2009","unstructured":"Dahabreh IJ, Zoi K, Giannouli S et al (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33(1):67\u201373","journal-title":"Leuk Res"},{"key":"706_CR20","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","volume":"93","author":"PD Ziakas","year":"2008","unstructured":"Ziakas PD (2008) Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 93:1412\u20131414","journal-title":"Haematologica"},{"issue":"16","key":"706_CR21","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","volume":"26","author":"A Carobbio","year":"2008","unstructured":"Carobbio A, Antonioli E, Guglielmelli P et al (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 26(16):2732\u20136","journal-title":"J Clin Oncol"},{"key":"706_CR22","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood.V112.11.1751.1751","volume":"112","author":"N Gangat","year":"2008","unstructured":"Gangat N, Wolanskyj A, Schwager S et al (2008) Leukocytosis at diagnosis and the risk of subsequent thrombosis in low-risk essential thrombocythemia and polycythemia vera. Blood 112:1751 (Abs)","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0706-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-009-0706-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0706-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T18:57:52Z","timestamp":1589569072000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-009-0706-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,13]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s00277-009-0706-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,13]]}}}